• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Chung-Welch Nancy was granted 2,353 shares, increasing direct ownership by 12% to 21,237 units (SEC Form 4)

    4/12/24 5:25:25 PM ET
    $POAI
    Industrial Specialties
    Health Care
    Get the next $POAI alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    CHUNG-WELCH NANCY

    (Last) (First) (Middle)
    P.O. BOX 1572

    (Street)
    PEPPERELL MA 01463

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Predictive Oncology Inc. [ POAI ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    04/05/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 04/05/2024 A 2,353 A $0 21,237 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    /s/Josh Blacher 04/12/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $POAI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $POAI

    DatePrice TargetRatingAnalyst
    8/19/2024$3.00Buy
    H.C. Wainwright
    6/30/2021$5.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $POAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    St. Clair Gregory Sr was granted 3,268 shares, increasing direct ownership by 17% to 22,534 units (SEC Form 4)

    4 - Predictive Oncology Inc. (0001446159) (Issuer)

    4/12/24 5:26:48 PM ET
    $POAI
    Industrial Specialties
    Health Care

    Hawryluk Matthew was granted 2,368 shares, increasing direct ownership by 33% to 9,488 units (SEC Form 4)

    4 - Predictive Oncology Inc. (0001446159) (Issuer)

    4/12/24 5:26:26 PM ET
    $POAI
    Industrial Specialties
    Health Care

    Rao Veena was granted 3,268 shares, increasing direct ownership by 56% to 9,117 units (SEC Form 4)

    4 - Predictive Oncology Inc. (0001446159) (Issuer)

    4/12/24 5:26:19 PM ET
    $POAI
    Industrial Specialties
    Health Care

    $POAI
    SEC Filings

    View All

    SEC Form DEF 14A filed by Predictive Oncology Inc.

    DEF 14A - Predictive Oncology Inc. (0001446159) (Filer)

    8/18/25 4:00:49 PM ET
    $POAI
    Industrial Specialties
    Health Care

    Predictive Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Predictive Oncology Inc. (0001446159) (Filer)

    8/14/25 7:00:43 AM ET
    $POAI
    Industrial Specialties
    Health Care

    SEC Form 10-Q filed by Predictive Oncology Inc.

    10-Q - Predictive Oncology Inc. (0001446159) (Filer)

    8/13/25 4:01:23 PM ET
    $POAI
    Industrial Specialties
    Health Care

    $POAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Predictive Oncology with a new price target

    H.C. Wainwright initiated coverage of Predictive Oncology with a rating of Buy and set a new price target of $3.00

    8/19/24 6:55:24 AM ET
    $POAI
    Industrial Specialties
    Health Care

    HC Wainwright & Co. initiated coverage on Predictive Oncology with a new price target

    HC Wainwright & Co. initiated coverage of Predictive Oncology with a rating of Buy and set a new price target of $5.00

    6/30/21 6:22:58 AM ET
    $POAI
    Industrial Specialties
    Health Care

    Litchfield Hills Research initiated coverage on Predictive Oncology with a new price target

    Litchfield Hills Research initiated coverage of Predictive Oncology with a rating of Buy and set a new price target of $3.00

    2/1/21 10:17:27 AM ET
    $POAI
    Industrial Specialties
    Health Care

    $POAI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Predictive Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    PITTSBURGH, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended June 30, 2025, and provided a corporate update. The Company reported a loss from continuing operations of approximately $2.0 million. Q2 2025 and Recent Highlights: Continued to advance preparations for an aggressive market expansion of ChemoFx®, its validated flagship live cell drug response assay, in t

    8/14/25 7:00:43 AM ET
    $POAI
    Industrial Specialties
    Health Care

    Predictive Oncology Issues Shareholder Letter: Well Financed to Support Expanded U.S. Availability and E.U. Launch of ChemoFx® and Pursuit of Other High-Value AI-Driven Drug Discovery and Development Opportunities

    $10 million securities purchase agreement provides efficient and flexible funding in support of strategic multi-million dollar growth initiatives Discussions underway to expand adoption of ChemoFx in the U.S. and accelerate initial launch in Europe PITTSBURGH, July 15, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery, today issued the following shareholder update: To my fellow Shareholders, The past several weeks have been particularly noteworthy and productive at Predictive Oncology, and I wanted to take this opportunity to provide a brief recap of recent developments. Preparing for aggressive market expansion of ChemoFx® in the U

    7/15/25 9:00:00 AM ET
    $POAI
    Industrial Specialties
    Health Care

    Predictive Oncology Announces $10M Share Purchase Agreement in Partnership with Yorkville Advisors to Advance AI-Driven Drug Discovery and Repurposing

    PITTSBURGH, July 08, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery, announced today that it has entered into a standby equity purchase agreement ("SEPA") with YA II PN, LTD, an investment fund managed by Yorkville Advisors Global, LP ("Yorkville"). Predictive Oncology expects the partnership to provide an efficient and flexible source of funding, enabling the company to progress its ongoing drug discovery, biomarker discovery and drug repurposing initiatives, and business development opportunities with leading biopharmaceutical companies, leveraging its novel AI and machine learning capabilities. Under the terms of the agreement, Pre

    7/8/25 9:00:00 AM ET
    $POAI
    Industrial Specialties
    Health Care

    $POAI
    Leadership Updates

    Live Leadership Updates

    View All

    AIRNA Appoints Matthew Hawryluk as Chief Business Officer

    AIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and common diseases, today announced the appointment of Matthew Hawryluk, Ph.D., MBA, as Chief Business Officer. Dr. Hawryluk brings vast leadership experience in the life sciences sector, with a proven track record of bridging scientific innovation and commercial application. "Matt is a tremendous addition to our leadership team, bringing extensive experience driving collaborations and leading high-performing teams," said Kris Elverum, President and CEO of AIRNA. "Matt joins us at a critical time, as we prepare to bring our first RNA editing therapeutic to the clinic. We have the pote

    1/30/25 7:00:00 AM ET
    $POAI
    Industrial Specialties
    Health Care

    Renovaro Issues Shareholder Letter and Provides Corporate Update

    Company to Host International Roadshow the Week of January 13, 2025 LOS ANGELES, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today issued a letter to shareholders from Chief Executive Officer David Weinstein. Dear Shareholders, As we enter the new year, I wanted to update you on the progress we have made in the last two months and further define our trajectory for 2025. Our comprehensive analysis of both businesses and development of a 100-day plan of action has already turned up some hidden value in both businesses and is helping us understand key areas of the business we need to for

    1/7/25 9:15:00 AM ET
    $POAI
    $RENB
    Industrial Specialties
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Predictive Oncology Appoints Biopharmaceutical Finance Veteran Mr. Andrew Einhorn to its Business Advisory Board

    EAGAN, Minn., June 27, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced the appointment of biopharmaceutical finance veteran Mr. Andrew Einhorn to its Business Advisory Board. "Andrew Einhorn brings a wealth of senior financial leadership experience in the biopharmaceutical industry to our Business Advisory Board, and I am very pleas

    6/27/23 8:00:00 AM ET
    $POAI
    Industrial Specialties
    Health Care

    $POAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Predictive Oncology Inc. (Amendment)

    SC 13G/A - Predictive Oncology Inc. (0001446159) (Subject)

    2/11/22 7:50:59 AM ET
    $POAI
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed

    SC 13G - Predictive Oncology Inc. (0001446159) (Subject)

    3/1/21 6:23:16 AM ET
    $POAI
    Industrial Specialties
    Health Care

    $POAI
    Financials

    Live finance-specific insights

    View All

    Predictive Oncology Reports Third Quarter 2024 Financial Results and Provides Strategic Update

    PITTSBURGH, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended September 30, 2024, and provided a corporate update. The Company reported a loss from continuing operations of approximately $2.3 million on total revenue of $345,686 for the quarter. Predictive Oncology also announced today that the company's Board of Directors, working with a strategic advisor, has i

    11/13/24 7:00:21 AM ET
    $POAI
    Industrial Specialties
    Health Care

    Predictive Oncology Reports Second Quarter 2024 Financial Results and Provides Business Update

    PITTSBURGH, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended June 30, 2024, and provided a corporate update. The Company reported a net loss of approximately $3.2 million on total revenue of approximately $0.3 million for the quarter. Q2 2024 and Recent Highlights: Entered biomarker discovery market following compelling results from retrospective ovarian cancer s

    8/14/24 7:00:00 AM ET
    $POAI
    Industrial Specialties
    Health Care

    Predictive Oncology to Report Second Quarter 2024 Financial Results on Wednesday, August 14, 2024

    PITTSBURGH, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced that it will report its financial results for the second quarter ended June 30, 2024 before the markets open on Wednesday, August 14, 2024. The company will host a corporate update conference call and live audio webcast at 8:30 a.m. ET. Live Conference Call & Webcas

    8/7/24 7:00:00 AM ET
    $POAI
    Industrial Specialties
    Health Care